metabolism. Avoid or Use Alternate Drug.ropinirolearipiprazole decreases effects of ropinirole by pharmacodynamic antagonism. Contraindicated.safinamidearipiprazole decreases effects of safinamide by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Dopamine antagonists may decrease safinamide effects and exacerbate Parkinson disease symptoms.saquinaviraripiprazole and saquinavir both increase QTc interval. Avoid or Use Alternate Drug.selinexorselinexor, aripiprazole. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.selpercatinibaripiprazole and selpercatinib both increase QTc interval. Avoid or Use Alternate Drug.siponimodaripiprazole and siponimod both increase QTc interval. Avoid or Use Alternate Drug.sodium oxybatearipiprazole, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.sorafenibaripiprazole and sorafenib both increase QTc interval. Avoid or Use Alternate Drug.sotalolaripiprazole and sotalol both increase QTc interval. Avoid or Use Alternate Drug.St John's WortSt John's Wort will decrease the level or effect of aripiprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.sufentanil SLsufentanil SL, aripiprazole. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration may result in hypotension, profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.tetrabenazinearipiprazole and tetrabenazine both increase QTc interval. Avoid or Use Alternate Drug.thiothixenearipiprazole and thiothixene both increase QTc interval. Avoid or Use Alternate Drug.tipranavirtipranavir will increase the level or effect of aripiprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.toremifenearipiprazole and toremifene both increase QTc interval. Avoid or Use Alternate Drug.trazodonearipiprazole and trazodone both increase QTc interval. Avoid or Use Alternate Drug.vandetanibaripiprazole and vandetanib both increase QTc interval. Avoid or Use Alternate Drug.vemurafenibaripiprazole and vemurafenib both increase QTc interval. Avoid or Use Alternate Drug.voriconazolearipiprazole and voriconazole both increase QTc interval. Avoid or Use Alternate Drug.vorinostataripiprazole and vorinostat both increase QTc interval. Avoid or Use Alternate Drug.voxelotorvoxelotor will increase the level or effect of aripiprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Voxelotor increases systemic exposure of sensitive CYP3A4 substrates. Avoid coadministration with sensitive CYP3A4 substrates with a narrow therapeutic index. Consider dose reduction of the sensitive CYP3A4 substrate(s) if unable to avoid.ziprasidonearipiprazole and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.Monitor Closely (412)abirateroneabiraterone increases levels of aripiprazole by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Avoid coadministration of abiraterone with substrates of CYP2D6. If alternative therapy cannot be used, exercise caution and consider a dose reduction of the CYP2D6 substrate.acarbosearipiprazole, acarbose. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.aclidiniumaclidinium decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.aripiprazole increases effects of aclidinium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.acrivastineacrivastine and aripiprazole both increase sedation. Use Caution/Monitor.albiglutidearipiprazole, albiglutide. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.albuterolaripiprazole increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.alfentanilalfentanil and aripiprazole both increase sedation. Use Caution/Monitor.alfuzosinaripiprazole and alfuzosin both increase QTc interval. Use Caution/Monitor.almotriptanalmotriptan, aripiprazole. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).alprazolamalprazolam and aripiprazole both increase sedation. Use Caution/Monitor.amifostineamifostine, aripiprazole. Either increases effects of the other by anti-hypertensive channel blocking. Use Caution/Monitor. Due to its alpha adrenergic antagonism, atypical antipsychotic agents has the potential to enhance the effect of certain antihypertensive agents. Monitor blood pressure and adjust dose accordingly.amitriptylinearipiprazole and amitriptyline both increase sedation. Use Caution/Monitor.aripiprazole and amitriptyline both increase QTc interval. Use Caution/Monitor.amobarbitalamobarbital and aripiprazole both increase sedation. Use Caution/Monitor.amoxapinearipiprazole and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.aripiprazole and amoxapine both increase sedation. Use Caution/Monitor.aripiprazole and amoxapine both increase QTc interval. Use Caution/Monitor.anagrelidearipiprazole and anagrelide both increase QTc interval. Use Caution/Monitor.anticholinergic/sedative combosanticholinergic/sedative combos decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.anticholinergic/sedative combos decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.aripiprazole increases effects of anticholinergic/sedative combos by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.apomorphinearipiprazole and apomorphine both increase sedation. Use Caution/Monitor.aripiprazole and apomorphine both increase QTc interval. Use Caution/Monitor.aprepitantaprepitant will increase the level or effect of aripiprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.arformoterolaripiprazole increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.aripiprazole and arformoterol both increase QTc interval. Use Caution/Monitor.armodafinilarmodafinil will decrease the level or effect of aripiprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.aripiprazole increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.artemether/lumefantrineartemether/lumefantrine will increase the level or effect of aripiprazole by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.artemether/lumefantrine will decrease the level or effect of aripiprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.asenapineasenapine and aripiprazole both increase sedation. Use Caution/Monitor.asenapine transdermalasenapine transdermal and aripiprazole both increase sedation. Use Caution/Monitor.atazanaviratazanavir will increase the level or effect of aripiprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.atracuriumatracurium decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.atracurium decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.aripiprazole increases effects of atracurium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.atropineatropine decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.atropine decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.aripiprazole increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.atropine IV/IMaripiprazole increases effects of atropine IV/IM by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.atropine IV/IM decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.atropine IV/IM decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.avapritinibavapritinib and aripiprazole both increase sedation. Use Caution/Monitor.azelastineazelastine and aripiprazole both increase sedation. Use Caution/Monitor.baclofenbaclofen and aripiprazole both increase sedation. Use Caution/Monitor.belladonna alkaloidsbelladonna alkaloids decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.belladonna alkaloids decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.aripiprazole increases effects of belladonna alkaloids by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.belladonna and opiumbelladonna and opium and aripiprazole both increase sedation. Use Caution/Monitor.belladonna and opium decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.belladonna and opium decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.aripiprazole increases effects of belladonna and opium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.belzutifanbelzutifan will decrease the level or effect of aripiprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. If unable to avoid coadministration of belzutifan with sensitive CYP3A4 substrates, consider increasing the sensitive CYP3A4 substrate dose in accordance with its prescribing information. benazeprilaripiprazole, benazepril. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypotensive effects.benperidolaripiprazole and benperidol both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.aripiprazole and benperidol both increase sedation. Use Caution/Monitor.benzhydrocodone/acetaminophenbenzhydrocodone/acetaminophen and aripiprazole both increase sedation. Use Caution/Monitor.benzphetaminearipiprazole increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.bosentanbosentan will decrease the level or effect of aripiprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.brexanolonebrexanolone, aripiprazole. Either increases toxicity of the other by sedation. Use Caution/Monitor.brexpiprazolebrexpiprazole and aripiprazole both increase sedation. Use Caution/Monitor.brimonidinebrimonidine and aripiprazole both increase sedation. Use Caution/Monitor.brivaracetambrivaracetam and aripiprazole both increase sedation. Use Caution/Monitor.brompheniraminebrompheniramine and aripiprazole both increase sedation. Use Caution/Monitor.budesonidebudesonide will decrease the level or effect of aripiprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.buprenorphinebuprenorphine and aripiprazole both increase sedation. Use Caution/Monitor.buprenorphine buccalbuprenorphine buccal and aripiprazole both increase sedation. Use Caution/Monitor.buprenorphine subdermal implantbuprenorphine subdermal implant and aripiprazole both increase sedation. Use Caution/Monitor.buprenorphine transdermalbuprenorphine transdermal and aripiprazole both increase sedation. Use Caution/Monitor.buprenorphine, long-acting injectionaripiprazole increases toxicity of buprenorphine, long-acting injection by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of buprenorphine and benzodiazepines or other CNS depressants increases risk of adverse reactions including overdose, respiratory depression, and death. Cessation of benzodiazepines or other CNS depressants is preferred in most cases. In some cases, monitoring at a higher level of care for tapering CNS depressants may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose may be appropriate.buprenorphine, long-acting injection and aripiprazole both increase sedation. Use Caution/Monitor.bupropionbupropion will increase the level or effect of aripiprazole by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.butabarbitalbutabarbital will decrease the level or effect of aripiprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.butabarbital and aripiprazole both increase sedation. Use Caution/Monitor.butalbitalbutalbital will decrease the level or effect of aripiprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.butalbital and aripiprazole both increase sedation. Use Caution/Monitor.butorphanolbutorphanol and aripiprazole both increase sedation. Use Caution/Monitor.caffeinearipiprazole increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.captoprilaripiprazole, captopril. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs lower blood pressure. Monitor blood pressure.carbinoxaminecarbinoxamine and aripiprazole both increase sedation. Use Caution/Monitor.carisoprodolcarisoprodol and aripiprazole both increase sedation. Use Caution/Monitor.cenobamatecenobamate will decrease the level or effect of aripiprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase dose of CYP3A4 substrate, as needed, when coadministered with cenobamate.cenobamate, aripiprazole. Either increases effects of the other by sedation. Use Caution/Monitor.chloral hydratechloral hydrate and aripiprazole both increase sedation. Use Caution/Monitor.chlordiazepoxidechlordiazepoxide and aripiprazole both increase sedation. Use Caution/Monitor.chlorpheniraminechlorpheniramine and aripiprazole both increase sedation. Use Caution/Monitor.chlorpromazinearipiprazole and chlorpromazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.aripiprazole and chlorpromazine both increase sedation. Use Caution/Monitor.chlorpropamidearipiprazole, chlorpropamide. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.chlorzoxazonechlorzoxazone and aripiprazole both increase sedation. Use Caution/Monitor.cinnarizinecinnarizine and aripiprazole both increase sedation. Use Caution/Monitor.ciprofloxacinaripiprazole and ciprofloxacin both increase QTc interval. Use Caution/Monitor.cisatracuriumcisatracurium decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.cisatracurium decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.aripiprazole increases effects of cisatracurium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.clemastineclemastine and aripiprazole both increase sedation. Use Caution/Monitor.clobazamclobazam will increase the level or effect of aripiprazole by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Lower doses of drugs metabolized by CYP2D6 may be required when used concomitantly. aripiprazole, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).clomipraminearipiprazole and clomipramine both increase sedation. Use Caution/Monitor.aripiprazole and clomipramine both increase QTc interval. Use Caution/Monitor.clonazepamclonazepam and aripiprazole both increase sedation. Use Caution/Monitor.clonidineclonidine, aripiprazole. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium.clorazepateclorazepate and aripiprazole both increase sedation. Use Caution/Monitor.clozapinearipiprazole and clozapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.aripiprazole and clozapine both increase sedation. Use Caution/Monitor.cobicistatcobicistat will increase the level or effect of aripiprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce aripiprazole dose by 25% and by approximately 50% if administered with CYP3A4 inhibitor and CYP206 inhibitorcodeinecodeine and aripiprazole both increase sedation. Use Caution/Monitor.conivaptanconivaptan will increase the level or effect of aripiprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.cortisonecortisone will decrease the level or effect of aripiprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.crizotinibcrizotinib increases levels of aripiprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.crofelemercrofelemer increases levels of aripiprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed.cyclizinecyclizine and aripiprazole both